

# CMFRI to sell seaweed-based nutraceutical

TIMES NEWS NETWORK

**Kochi:** A patent-protected nutraceutical product developed by Central Marine Fisheries Research Institute (CMFRI) from seaweeds to combat non-alcoholic fatty liver disease will hit the market soon.

The CMFRI has signed an MoU with a private company dealing with health products for commercial production

and marketing of Cadalmin LivCure extract. A unique blend of 100% natural bioactive ingredients extracted from select seaweeds, the product is made using an eco-friendly technology to improve liver health and is the ninth nutraceutical developed by the CMFRI.

Nutraceuticals are any substance that is a food or part of a food and provides medi-

cal or health benefits, including the prevention and treatment of disease. CMFRI has commercialised nutraceuticals to combat lifestyle diseases and an immunity booster.

“Commercialisation of the product will be beneficial to a large number of people suffering from non-alcoholic fatty liver disease as it helps improve liver health, reduce disposition of fatty substance

and maintain other liver/lipid parameters within the clinically acceptable limits,” said CMFRI director Dr A Gopalakrishnan, adding that it does not have any side effects as established by trials.

The product would hit the market within four months and would be made available online as well as physical markets, said Emineotech MD Evanjalist Pathrose.